FDA Issues Reminder on Risk for Serious Fungal Infections With TNF-alpha Blockers, Including Simponi
May 29, 2009 — The US Food and Drug Administration (FDA) has issued a reminder on the risk for serious fungal infections associated with all tumor necrosis factor-alpha (TNF-alpha) inhibitors, ...
WASHINGTON (Reuters) - U.S. health regulators ordered stronger warnings for prescription drugs to treat rheumatoid arthritis, Crohn's disease and other conditions on Thursday after dozens of patients ...
Tumor necrosis factor (TNF)–alpha inhibitors achieve better endoscopic healing than the newer biologic drugs vedolizumab (Entyvio) and ustekinumab (Stelara) in moderate to severe Crohn's disease, a ...
Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...
NEW YORK (Reuters Health) - Three available drugs that belong to the newest class of drugs for treating rheumatoid arthritis -- the tumor necrosis factor (TNF)-alpha blockers -- are equally effective ...
> FDA is tacking new, stronger warnings on TNF-alpha blockers. The new label language highlights an increased risk of cancer in children and adolescents who take the blockbuster meds. Report > ...
Transformative potential for novel TNF-alpha inhibitor drug: Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc.
Surgical closure of perianal fistulas in Crohn's disease (CD), when combined with short-term tumor necrosis factor (TNF) inhibitors, improved radiologic healing and other outcomes compared to ...
LISA‑TRACKER enzyme‑linked immunosorbent assay (ELISA) kits are manufactured by Theradiag and distributed in the UK by Alpha Laboratories. There are 6 LISA‑TRACKER ELISA kits relevant to this ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...
The diagnostics advisory committee considered evidence on enzyme-linked immunosorbent assay (ELISA) tests (Promonitor, IDKmonitor, LISA‑TRACKER, RIDASCREEN, MabTrack, and tests used by Sanquin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results